Insulet (Nasdaq:PODD) shares were down after hours despite first-quarter results that topped the consensus forecast.
The Acton, Massachusetts-based automated insulin technology developer posted profits of $27.8 million, or 40¢ per share, on sales of $295.4 million for the three months ended March 31, 2022, for a big bottom-line gain from breakeven this time a year ago on sales growth of 17.1%.
Insulet, the maker of the Omnipod 5 automated insulin delivery system, which garnered FDA clearance during the quarter, saw its EPS come in 17¢ ahead of projections on Wall Street, where analysts were looking for sales of $288.2 million.
Get the full story at our sister site, Drug Delivery Business News.